Pomerantz investigates Celsius Holdings over marketing claims
Pomerantz LLP is investigating Celsius Holdings, Inc. for potential securities fraud following a Texas inquiry into marketing claims. The firm is examining whether Celsius and its officers violated federal securities laws. On June 4, 2026, Celsius stock fell 7.53% to $27.75 per share.

*this image is generated using AI for illustrative purposes only.
Pomerantz LLP is investigating claims on behalf of investors of Celsius Holdings, Inc. concerning potential securities fraud and other unlawful business practices. The law firm is examining whether Celsius and certain officers and/or directors violated federal securities laws. Investors are advised to contact Danielle Peyton to discuss their legal rights.
The investigation stems from an announcement by Texas Attorney General Ken Paxton on June 4, 2026. Paxton revealed an inquiry into whether Celsius and its subsidiary, Alani Nutrition, violated the Texas Deceptive Trade Practices Act. The state is scrutinizing allegations that the companies misrepresented the safety of their highly caffeinated energy drinks while marketing them to children and teens.
Following the news of the Texas investigation, Celsius Holdings experienced a significant decline in its stock price. On June 4, 2026, the stock fell $2.26 per share, a drop of 7.53%, to close at $27.75 per share.
Key Stock Movement
| Date | Closing Price ($) | Change ($) | Change (%) |
|---|---|---|---|
| June 4, 2026 | 27.75 | -2.26 | -7.53 |
Pomerantz LLP, with offices in major cities including New York and Chicago, is recognized as a premier firm in corporate and securities class litigation. The firm focuses on recovering damages for victims of securities fraud, breaches of fiduciary duty, and corporate misconduct.
How might the Texas investigation influence other states to launch similar inquiries into Celsius's marketing practices?
What potential long-term impacts could the allegations have on Celsius's brand reputation among parents and young consumers?
Could the legal scrutiny lead to changes in Celsius's product formulations or labeling to address safety concerns?































